Published TCIMAIL newest issue No.196
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 231277-92-2 | Product Number: L0360
Lapatinib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 250MG |
€96.00
|
2 | 6 |
|
| 1G |
€247.00
|
1 | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | L0360 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__9H__2__6ClFN__4O__4S = 581.06 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 231277-92-2 |
| Reaxys Registry Number | 10502247 |
| PubChem Substance ID | 468592164 |
| MDL Number | MFCD09264194 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 145.0 to 149.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 147 °C |
| Maximum Absorption Wavelength | 367(MeOH) nm |
GHS
| Hazard Statements | H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
Related Laws:
| RTECS# | VA0952500 |
Transport Information:
| HS Number | 2934999090 |
Application
Lapatinib: A Dual Kinase Inhibitor of EGFR and HER2
Lapatinib (GW572016) is a 4-anilinoquinazoline dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. Advanced breast cancer or metastatic breast cancer often overexpress HER2 which is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Lapatinib plus capecitabine [C2878] (a prodrug of 5-FU [F0151]) has shown potent activity in solid tumors, with the most notable in advanced or metastatic breast cancer. (The product is for research purpose only.)
References
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases (a review)
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.